Pearl River Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Pearl River Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,814	Closed	-$3.14M	–	599
2023 Q3	$3.14M	Sell	3,814 -3,019	-44%	-$2.37M	0.49%	50
2023 Q2	$4.91M	Buy	6,833 +3,960	+138%	+$3.05M	0.79%	17
2023 Q1	$2.36M	Sell	2,873 -46	-2%	-$34.7K	0.37%	76
2022 Q4	$2.11M	Sell	2,919 -724	-20%	-$534K	0.36%	80
2022 Q3	$2.51M	Sell	3,643 -1,715	-32%	-$1.08M	0.47%	53
2022 Q2	$3.17M	Buy	+5,358	New	+$3.48M	0.74%	24
2022 Q1	–	Sell	-3,420	Closed	-$2.16M	–	535
2021 Q4	$2.16M	Buy	+3,420	New	+$2.1M	0.58%	39
2021 Q2	–	Sell	-4,548	Closed	-$2.15M	–	548
2021 Q1	$2.15M	Buy	4,548 +1,112	+32%	+$541K	0.69%	35
2020 Q4	$1.66M	Buy	+3,436	New	+$1.85M	0.59%	36
2020 Q2	–	Sell	-156	Closed	-$76K	–	522
2020 Q1	$76K	Buy	+156	New	+$64.3K	0.15%	188
2019 Q3	–	Sell	-312	Closed	-$98K	–	503
2019 Q2	$98K	Buy	+312	New	+$104K	0.63%	75

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Pearl River Capital's REGN Position: Q4 2023 in Review

Pearl River Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 3,814 shares — an estimated $3.14M sold.

Pearl River Capital first reported a position in REGN in Q2 2019 and held it in 11 quarters. The position peaked at $4.91M in Q2 2023. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Pearl River Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Pearl River Capital sold 3,814 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $3.14M.
Pearl River Capital first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 11 quarters.
Pearl River Capital's Regeneron Pharmaceuticals position peaked at $4.91M in Q2 2023.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Pearl River Capital's 13F filing for Q4 2023, filed 13 Feb 2024.